Alpha 2.0
Login Register
» Authors » Piotr Czubkowski

Piotr Czubkowski

Explore the profile of Piotr Czubkowski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 625
Followers 0
Related Specialties
Gastroenterology
General Surgery
Pediatrics
Top 10 Co-Authors
Irena Jankowska
Joanna Pawlowska
Piotr Socha
Piotr Kalicinski
Dominique Debray
Florence Lacaille
Bjorn Fischler
Henkjan J Verkade
Etienne Sokal
Richard J Thompson
Published In
J Pediatr Gastroenterol Nutr
Ann Transplant
Pediatr Transplant
J Clin Med
Hepatology
Affiliations
Soon will be listed here.
Recent Articles
1.
Classical autoimmune hepatitis and the IgG4-associated autoimmune hepatitis in paediatric patients
Kaps-Kopiec D, Wozniak M, Jarzebicka D, Grzywa-Czuba R, Pawlowska J, Czubkowski P, et al.
Pol J Pathol . 2024 Aug; 75(2):153-156. PMID: 39166523
The IgG4-associated autoimmune hepatitis (IgG4-AIH) is a newly proposed disease entity characterised by the accumulation of the IgG4-expressing plasma cells in the liver. Its pathophysiology and clinical significance remain unclear...
2.
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Miethke A, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F, et al.
Lancet Gastroenterol Hepatol . 2024 May; 9(7):620-631. PMID: 38723644
Background: Progressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive disorders, the most prevalent being BSEP deficiency, resulting in disrupted bile formation, cholestasis, and pruritus. Building on a...
3.
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
Ovchinsky N, Aumar M, Baker A, Baumann U, Bufler P, Cananzi M, et al.
Lancet Gastroenterol Hepatol . 2024 Apr; 9(7):632-645. PMID: 38670135
Background: In patients with Alagille syndrome, cholestasis-associated clinical features can include high serum bile acids and severe pruritus that can necessitate liver transplantation. We aimed to evaluate the efficacy and...
4.
Awareness, referral and age at Kasai surgery for biliary atresia in Europe: A survey of the Quality-of-Care Task Force of ESPGHAN
Lacaille F, Nicastro E, Czubkowski P, Goncalves C, Le Thi T, Koletzko S
J Pediatr Gastroenterol Nutr . 2024 Mar; 78(6):1374-1382. PMID: 38497334
Objectives: To identify infants with biliary atresia (BA), European Society of Paediatric Gastroenteroloy and Nutrition (ESPGHAN)/North American Society of Pediatric Gastroenteroloy and Nutrition (NASPGHAN) guidelines recommend measurement of conjugated/direct bilirubin...
5.
Anthropometric assessment: ESPGHAN quality of care survey from paediatric hospitals in 28 European countries
Litwin A, Le Thi T, Pancheva R, Niseteo T, Hauer A, Kindermann A, et al.
J Pediatr Gastroenterol Nutr . 2024 Jan; 78(4):936-947. PMID: 38284746
Objectives: Assessment of anthropometric data is essential for paediatric healthcare. We surveyed the implementation of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) evidence-based guidelines and practical recommendations on...
6.
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA
Hansen B, Vandriel S, Vig P, Garner W, Mogul D, Loomes K, et al.
Hepatology . 2023 Dec; 79(6):1279-1292. PMID: 38146932
Background And Aims: Alagille syndrome (ALGS) is characterized by chronic cholestasis with associated pruritus and extrahepatic anomalies. Maralixibat, an ileal bile acid transporter inhibitor, is an approved pharmacologic therapy for...
7.
The relationship between 6-thioguanine levels and remission outcomes in children with autoimmune hepatitis. Single center experience
Kaps-Kopiec D, Czajkowska A, Gorska M, Wozniak M, Jarzebicka D, Cielecka-Kuszyk J, et al.
Clin Exp Hepatol . 2023 Jul; 9(2):115-121. PMID: 37502437
Aim Of The Study: The treatment of autoimmune hepatitis (AIH) is based on steroids and azathioprine (AZA). AZA is a pro-drug which is converted among others into 6-thioguanine (6-TG) and...
8.
Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
Thompson R, Artan R, Baumann U, Calvo P, Czubkowski P, Dalgic B, et al.
JHEP Rep . 2023 Jul; 5(8):100782. PMID: 37456676
Background & Aims: PEDFIC 2, an ongoing, open-label, 72-week study, evaluates odevixibat, an ileal bile acid transporter inhibitor, in patients with progressive familial intrahepatic cholestasis. Methods: PEDFIC 2 enrolled and...
9.
Tissue Expression of Programmed Cell Death 1 Ligand1 (PD-L1) in Biopsies of Transplant Livers of Pediatric Patients as a Possible Marker of Acute Cellular Rejection
Szymanska S, Markiewicz-Kijewska M, Pyzlak M, Karkucinska-Wienckowska A, Ciopinski M, Czubkowski P, et al.
J Clin Med . 2023 Jul; 12(13). PMID: 37445304
Introduction: Preclinical models have demonstrated that PD-1 and its ligand programmed death ligand1 (PD-L1) play significant roles in both graft induction and the maintenance of immune tolerance. It has also...
10.
Is M30 staining a reliable marker predicting graft rejection and fibrosis in protocolar liver biopsies in post-liver transplant pediatric patients?
Szymanska S, Markiewicz-Kijewska M, Pyzlak M, Kalicinski P, Teisseyre J, Czubkowski P, et al.
Minerva Pediatr (Torino) . 2023 Jun; PMID: 37284810
Background: Liver transplantation is currently a treatment of choice in patients with end-stage liver disease. Acute cellular rejection (ACR), antibody-mediated rejection (AMR), and chronic rejection (ChR) are major causes of...